These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 159041)

  • 1. Stimulation of fibrinolysis in the vitreous body.
    Pandolfi M
    Bibl Anat; 1979; (18):292-7. PubMed ID: 159041
    [No Abstract]   [Full Text] [Related]  

  • 2. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis.
    Thorsen S; Astrup T
    Thromb Diath Haemorrh; 1974 Dec; 32(2-3):306-24. PubMed ID: 4281113
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhancement of vitreous clot lysis by urokinase: mode of action.
    Forrester JV; Edgar W; Millar W; Prentice CR; Williamson J
    Exp Eye Res; 1982 Jun; 34(6):895-907. PubMed ID: 6211365
    [No Abstract]   [Full Text] [Related]  

  • 4. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolytic activity of the vitreous body.
    Forrester JV; Prentice CR; Williamson J; Forbes CD
    Invest Ophthalmol; 1974 Nov; 13(11):875-9. PubMed ID: 4279343
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
    Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
    Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition by ethanol and acetaldehyde the plasmin activity and plasminogen activation induced by urokinase and streptokinase].
    Roszkowska-Jakimiec W; Jurkowski J; Ostrowska H; Worowski K
    Rocz Akad Med Bialymst (1989); 1988-1989; 33-34():53-66. PubMed ID: 2979011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic activity and localization of plasminogen activator in bovine vitreous body and aqueous humor.
    Hayashi K; Nakashima Y; Sueishi K; Tanaka K
    Jpn J Ophthalmol; 1989; 33(1):66-75. PubMed ID: 2499726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical and histochemical investigations on in vivo thrombolysis with urokinase in rabbits.
    Hisano S; Sueishi K; Ishii Y; Tanaka K
    Thromb Haemost; 1979 Jun; 41(4):796-803. PubMed ID: 483251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
    Matsuda T
    Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
    [No Abstract]   [Full Text] [Related]  

  • 15. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
    Thorsen S
    Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205
    [No Abstract]   [Full Text] [Related]  

  • 16. Tissue type plasminogen activator facilitates NMDA-receptor-mediated retinal apoptosis through an independent fibrinolytic cascade.
    Kumada M; Niwa M; Hara A; Matsuno H; Mori H; Ueshima S; Matsuo O; Yamamoto T; Kozawa O
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1504-7. PubMed ID: 15790922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
    Liu JN; Gurewich V
    J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
    Paloma MJ; Páramo JA; Rocha E
    Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
    Bode C; Eberle T; Runge M; Haber E; Kübler W
    Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.